Opelconazole (PC-945) is an experimental antifungal drug and the first triazole delivered via inhalation.[1][2][3] The drug is in Phase III and Phase II trials as of 2023.[4]

Opelconazole
Clinical data
Other namesPC-945
Legal status
Legal status
  • Investigational
Identifiers
  • 4-[4-[4-[[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]-3-methylphenyl]piperazin-1-yl]-N-(4-fluorophenyl)benzamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC38H37F3N6O3
Molar mass682.748 g·mol−1

References

edit
  1. ^ Wiederhold, Nathan P. (August 2022). "Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents". Journal of Fungi. 8 (8): 857. doi:10.3390/jof8080857. ISSN 2309-608X. PMC 9410397. PMID 36012845.
  2. ^ Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (3 June 2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
  3. ^ Ito, Kazuhiro (2022). "Inhaled antifungal therapy: benefits, challenges, and clinical applications". Expert Opinion on Drug Delivery. 19 (7): 755–769. doi:10.1080/17425247.2022.2084530. PMID 35634895.
  4. ^ "Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole". BioSpace. Retrieved 4 November 2023.